For the quarter ending 2025-09-30, COCP made $2,085,000 in revenue. -$2,049,000 in net income. Net profit margin of -98.27%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | |
|---|---|---|---|---|
| Stock-based compensation | - | - | 160,750 | |
| Salaries and personnel costs | - | - | 725,000 | |
| Research and development | 954,000 | 1,122,000 | 3,134,250 | |
| Other income | - | - | -93,500 | |
| General and administrative | 1,135,000 | 986,000 | - | |
| Total operating expenses | 2,089,000 | 2,108,000 | 4,469,500 | |
| Loss from operations | -2,089,000 | -2,108,000 | - | |
| Interest income | -22,000 | -28,000 | - | |
| Foreign exchange gain (loss) | 18,000 | 25,000 | - | |
| Insurance | - | - | 4,350,000 | |
| Total other income, net | 40,000 | 53,000 | - | |
| Net loss | -2,049,000 | -2,055,000 | -4,376,000 | |
| Net loss per common share, basic | -0.19 | -0.2 | -0.43 | |
| Net loss per common share, diluted | -0.19 | -0.2 | -0.43 | |
| Weighted average number of common shares, basic | 10,991,000 | 10,174,000 | 2,543,500 | |
| Weighted average number of common shares, diluted | 10,991,000 | 10,174,000 | 2,543,500 | |
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)